PACIFIC BIOSCIENCES of CALIF

Pacific Biosciences (PACB) stocks dip 3.7% yet tech leadership, new oncology assays, and a strong 46% monthly gain keep investors eyeing long‑term growth in genomics.

Pacific Biosciences of California surges 9.18% as SMRT sequencing drives strong earnings, clinical adoption, and investor confidence.

Pacific Biosciences stock surges 6.5% as SMRT single‑molecule sequencing drives growth—outperforming peers and positioning for long‑term biotech success.

Pacific Biosciences of California surges 6.36 %, breaking 200‑day SMA to a $537.7 million market cap—investors weigh biotech hype versus solid tech gains.